• Onena Medicines

  Led · Equity · Nov 2023

  Onena Medicines is developing a pipeline of antibodies that modulate Dual SMAD Inhibiting Proteins (DSIPs). The company’s flagship program, OMED-1, is a humanized LEFTY neutralizing antibody that has shown in vivo efficacy in preclinical breast, colorectal and glioblastoma models. Onena uses deep learning pipelines to humanize and optimize binding affinity and plans to select a development candidate for OMED-1. Its second program, OMED-2, is a fully human antibody against an undisclosed DSIP target the company believes may affect solid tumors such as melanoma. The current financing is intended to accelerate the development of these DSIP-modulating antibody programs and to advance OMED-2 through in vivo proof-of-concept. Onena operates out of Basel and San Sebastian, Spain, and is a BaseLaunch portfolio company.

• Nanoligent

  Led · Equity · Feb 2022

  Nanoligent is a Barcelona-based biotechnology firm focused on creating precision nanodrugs designed to combat cancer. Its technology centers on nanoscale drug constructs aimed at delivering anti-cancer agents directly to tumor cells while sparing healthy tissue. The company positions its platform as a next-generation therapeutic approach intended to improve treatment efficacy and reduce side effects compared with conventional chemotherapy. Nanoligent has attracted investor interest for its novel mechanism and potential to address significant unmet medical needs in oncology. To accelerate development, the company secured new capital in its latest financing round. This additional funding is intended to support continued research, preclinical development, and the progression of its drug candidates toward clinical evaluation.

No current team members are available.